Dabigatran etexilate Completed Phase N/A Trials for Hemorrhage / Nonvalvular Atrial Fibrillation

CompletedNot AvailableNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT02149303Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
NCT02849509Patient Convenience Study- NIS RELATE
NCT03254134Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03258645This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
NCT02240667Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
NCT03441633Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
NCT03187197Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
NCT03006341Validation of Predictors of OAC Initiation Using EMR Data
NCT01774370SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
NCT03254147Medical Need of OAC Reversal
NCT03189069A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
NCT02864758Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
NCT02631057Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
NCT02792335Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
NCT02769078Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
NCT02687867Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist